Kardiyovasküler hastalığı olan kadınlarda kontrasepsiyon ve danışmanlık

Kardiyovasküler hastalığı (KVH) olan kadınların gebeliklerinde ma - ternal ve neonatal morbidite, mortalite riski yüksektir. Gebe kalma - dan önce sağlığın optimize edilememesi durumunda planlanmamış gebelikler oldukça risklidir. Planlanmamış gebeliklerin bilinen riskleri - ne rağmen, KVH’ı olan kadınların %25 ila %54’ünde planlanmamış gebelikler devam etmektedir. Bu popülasyonda hem annenin hem de bebeğin sağlığını optimize etmek için gebelik öncesi güvenilir kontra - sepsiyon danışmanlığı ve gebelik planlaması yapılması önemlidir. KVH’ı olan üreme çağındaki kadınlara erken ve doğru kontraseptif danışmanlık yapılması, bu populasyonda planlanmamış gebeliklerin önlenmesi için zorunludur. Bu derlemenin amacı; KVH’ı olan kadınlarda kontraseptif yöntem seçeneklerini tanımlamak, danışmanlık kapsamında riskleri, ya- rarları ve kontraseptif yöntem tıbbi uygunluk kriterlerini literatür doğ - rultusunda incelemektir.

Contraception and counseling for women with cardiovascular disease

The risk of maternal and neonatal morbidity and mortality is high in pregnancies of women that they have cardiovascular disease (CVD). Unplanned pregnancies are very risky if health cannot be optimized before conception. Despite the known risks of unplanned pregnancies, 25% to 54% of women with cardiovascular heart disease continue to have unplanned pregnancies. It is important to provide reliable contraception counseling and pregnancy planning before pregnancy to optimize the health of both mother and baby in this population. Early and accurate contraceptive counseling for women of reproductive age with cardiovascular heart disease is must to prevent unplanned pregnancies in this population. The purpose of this review; To define contraceptive method options in women with cardiovascular heart disease, to examine the risks, benefits and contraceptive method medical eligibility criteria within the scope of counseling in line with the literature.

PDF

___

1. Anderson KN, Tepper NK, Downing K, Ailes EC, Abarbanell G, Farr SL. Contraceptive methods of privately insured US women with congenital heart defects. Am Heart J. 2020;222:38–45. [CrossRef]
2. Lindley KJ, Bairey Merz CN, Davis MB, Madden T, Park K, Bello NA; American College of Cardiology Cardiovascular Disease in Women Committee and the Cardio-Obstetrics Work Group. Contraception and reproductive planning for women with cardiovascular disease: JACC Focus Seminar 5/5. J Am Coll Cardiol. 2021;77:1823–34. [CrossRef]
3. Okoth K, Chandan JS, Marshall T, Thangaratinam S, Thomas GN, Nirantharakumar K, Adderley NJ. Association between the reproductive health of young women and cardiovascular disease in later life: umbrella review [published correction appears in BMJ. 2020;371:m3963. [CrossRef]
4. Fry KM, Gerhardt CA, Ash J, Zaidi AN, Garg V, McBride KL, Fitzgerald-Butt SM. Lifetime prevalence of sexual intercourse and contraception use at last sex among adolescents and young adults with congenital heart disease. J Adolesc Health. 2015;56:396–401. [CrossRef]
5. Abdalla M, Mancini DM. Management of pregnancy in the post cardiac transplant patient. Semin Perinatol. 2014;38:318–25. [CrossRef]
6. Maroo A, Chahine J. Contraceptive strategies in women with heart failure or with cardiac transplantation. Curr Heart Fail Rep. 2018;15:161–70. [CrossRef]
7. Faculty of Sexual & Reproductive Healthcare. UK Medical Eligibility Criteria for Contraceptive Use. UKMEC 2016. London: Faculty of Sexual & Reproductive Healthcare; 2016. https://www. fsrh.org/standards-and-guidance/external/ukmec-2016-digital version/
8. Jakes AD, Coad F, Nelson Piercy C. A review of contraceptive methods for women with cardiac disease. Obstet Gynaecol. 2018;20:21–9. [CrossRef]
9. Britton LE, Alspaugh A, Greene MZ, McLemore MR. CE. An evidence-based update on contraception. Am J Nurs. 2020;120:22– 33. [CrossRef]
10. Abarbanell G, Tepper NK, Farr SL. Safety of contraceptive use among women with congenital heart disease: a systematic review. Congenit Heart Dis. 2019;14:331–40. [CrossRef]
11. Lindley KJ, Madden T, Cahill AG, Ludbrook PA, Billadello JJ. Contraceptive use and unintended pregnancy in women with congenital heart disease. Obstet Gynecol. 2015;126:363–9. [CrossRef]
12. Roos-Hesselink JW, Cornette J, Sliwa K, Pieper PG, Veldtman GR, Johnson MR. Contraception and cardiovascular disease. Eur Heart J. 2015;36:1728–34b. [CrossRef]
13. World Health Organization. Medical eligibility criteria for contraceptive use: executive summary, 5th ed. Geneva: World Health Organization; 2015. https://www.who.int/publications/i/ item/WHO-RHR-15.07
14. Roach RE, Helmerhorst FM, Lijfering WM, Stijnen T, Algra A, Dekkers OM. Combined oral contraceptives: the risk of myocardial infarction and ischemic stroke. Cochrane Database Syst Rev. 2015;2015:CD011054. [CrossRef]
15. Comma ZM, Dehghani A, Fallahzadeh H, Koohgardi M, Dafei M, Mohammadi M. Effects of low-dose contraceptive pills on the risk factors of cardiovascular diseases among 15-35-year-old women: a retrospective cohort. Int J Reprod Biomed. 2019;17:841–50. [CrossRef]
16. Jimoh OS, Abdul IF, Balogun OR, Biliaminu SA, Adeniran AS, Jimoh-Abdulghaffaar HO, et al. Atherogenic and cardiovascular risks of women on combined oral contraceptives: a comparative study. Niger J Clin Pract. 2021;24:1759–65. [CrossRef]
17. Barsky L, Shufelt C, Lauzon M, Johnson BD, Berga SL, Braunstein G, et al. Prior oral contraceptive use and longer term mortality outcomes in women with suspected ıschemic heart disease. J Womens Health (Larchmt). 2021;30:377–84. [CrossRef]
18. Goldenberg I, Younis A, Huang DT, Yoruk A, Rosero SZ, Cutter K, et al. Use of oral contraceptives in women with congenital long QT syndrome. Heart Rhythm. 2022;19:41–8. [CrossRef]
19. Salem JE, Dureau P, Bachelot A, Germain M, Voiriot P, Lebourgeois B, et al. Association of oral contraceptives with drug-induced QT interval prolongation in healthy nonmenopausal women. JAMA Cardiol. 2018;3:877–82. [CrossRef]
20. Centers for Disease Control and Prevention (CDC). US medical eligibility criteria for contraceptive use; 2010. MMWR Recomm Rep 2010;59(No. RR-4). Erişim Tarihi: 23.06.2022. https://www. cdc.gov/reproductivehealth/contraception/mmwr/mec/summary. html
21. Glisic M, Shahzad S, Tsoli S, Chadni M, Asllanaj E, Rojas LZ, et al. Association between progestin-only contraceptive use and cardiometabolic outcomes: A systematic review and meta-analysis. Eur J Prev Cardiol. 2018;25:1042–52. [CrossRef]
22. Dilshad H, Yousuf RI, Shoaib MH, Jamil S, Khatoon H. Cardiovascular disease risk associated with the long-term use of depot medroxyprogesterone acetate. Am J Med Sci. 2016;352:487– 492. [CrossRef]
23. Bahamondes L, Fernandes A, Monteiro I, Bahamondes MV. Long acting reversible contraceptive (LARCs) methods. Best Pract Res Clin Obstet Gynaecol. 2020;66:28–40. [CrossRef]
24. Moraes LG, Marchi NM, Pitoli AC, Hidalgo MM, Silveira C, Modesto W, Bahamondes L. Assessment of the quality of cervical mucus among users of the levonorgestrel-releasing intrauterine system at different times of use. Eur J Contracept Reprod Health Care. 2016;21:318–22. [CrossRef]
25. Lanzola EL, Ketvertis K. Intrauterine device. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021.
26. Tepper NK, Dragoman MV, Gaffield ME, Curtis KM. Nonoral combined hormonal contraceptives and thromboembolism: a systematic review. Contraception. 2017;95:130–9. [CrossRef]
27. FSRH Clinical Effectiveness Unit (CEU). Contraceptive choices for women with cardiac disease. London: Faculty of Sexual & Reproductive Healthcare; 2014.
28. Braga GC, Brito MB, Ferriani RA, Oliveira LC, Garcia AA, Pintão MC, Vieira CS. Effect of the levonorgestrel-releasing intrauterine system on cardiovascular risk markers among women with thrombophilia or previous venous thromboembolism. Int J Gynaecol Obstet. 2020;148:381–5. [CrossRef]
29. Vu Q, Micks E, McCoy E, Prager S. Efficacy and safety of long acting reversible contraception in women with cardiovascular conditions. Am J Cardiol. 2016;117:302–4. [CrossRef]
30. Moss C, Isley MM. Sterilization: a review and update. Obstet Gynecol Clin North Am. 2015;42:713–24. [CrossRef]
31. Hatcher RA, Nelson AL, Trussell J, Cwiak C, Cason P, Policar MS, et al. Contraceptive Technology, 21st ed. Atlanta: Managing Contraception, LLC; 2018.
32. Shen J, Che Y, Showell E, Chen K, Cheng L. Interventions for emergency contraception. Cochrane Database Syst Rev. 2017;8:CD001324. [CrossRef]
33. Upadhya KK; Committee on Adolescence. Emergency contraception. Pediatrics. 2019;144:e20193149. [CrossRef]